Microbix Biosystms (TSE:MBX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Microbix Biosystems Inc. reports a robust third quarter in fiscal 2024 with $5.1 million in revenue and a net income of $0.25 million, driven by a 20% increase in sales of diagnostic-test components. The company’s growth is attributed to strong sales of Antigens and QAPs products, and it expects continued sales growth and progress with its Kinlytic product’s FDA re-approval.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.
